Recently, Biocompounds Pharmaceutical Inc. officially passed the review of the "Little Giant" enterprise program organized by the Ministry of Industry and Information Technology, successfully renewing this national-level honor. Specialization, refinement, and innovation are important strategies for promoting the high-quality development of SMEs in China, emphasizing the comprehensive performance of enterprises in four dimensions: specialization, refinement, distinctiveness, and innovation. "Little Giant" enterprises are benchmarks selected from the best, representing leading positions in their respective niche fields with technological leadership, high market share, strong innovation capabilities, outstanding growth potential, and mastery of key core technologies.

Since the Ministry of Industry and Information Technology launched the "Little Giant" enterprise cultivation program in 2019, enterprises have undergone multiple rigorous screening processes, including local preliminary review, provincial recommendation, and national review, and are subject to a review three years later. The review not only assesses the current strength of the enterprise but also focuses on its continuous innovation capabilities, the maintenance of its core competitiveness, and the actual effectiveness of "addressing weaknesses and strengthening strengths" in the industrial chain.

Passing the review is a recognition of Shanghai North Carolina's steady development and continuous innovation over the past three years. It not only instills confidence in the company's high-quality development in the next stage but also further consolidates its leading position and benchmark image in the industry. According to relevant policies in Shanghai, companies that pass the review will continue to enjoy support measures such as R&D expense deduction and policy-based guarantees, further enhancing their competitive advantages of being "small but beautiful, specialized and strong."